Venture Capital

Novartis's acquisition of Myricx Bio isn't just a deal. It's a story of academic grit, venture capital vision, and a new blueprint for patient-centric cancer therapy.

Beyond software, a new breed of venture capital is funding America's industrial rebirth, pouring millions into AI, robotics, and the factories of the future.

Balerion Space Ventures' hire of a top engineer signals a major shift. In deep tech, the sharpest minds are no longer just building—they're investing.

A new corporate venture fund by Pegasus Tech Ventures and Japan's Asteria Corp. isn't just about capital; it's a strategic bridge to redefine global innovation.

The world's only lupus-focused fund is betting on a new model blending VC rigor with patient-led strategy. But can this ambitious structure deliver real progress?

Forget the crypto hype. A top VC's success with IPOs and acquisitions reveals a quieter, more profound shift towards a mature, value-driven Web3.

With a new $155M fund, Larsen Jensen's firm is arming deep tech startups to win the next geopolitical race, blending military strategy with venture capital.

With a focus on AI, deepfake detection, and core infrastructure, the latest Sanabil Accelerator cohort reveals a strategic bet on regional resilience and global scale.

A 40% drop in early-stage funding reveals a stark reality: Canada's venture capital is consolidating, creating an 'innovation gap' that threatens the nation's future.

Humanoid Global's new partnership aims to unlock Asia's robotics boom. But this bet on the future hinges on a new advisory firm and a non-binding pact.

As the European Venture Fair marks 25 years, its intimate, 'by investors, for investors' model proves more vital than ever for tackling fusion, AI, and the future.

As it turns 50, Menlo Ventures bets a historic $3B on the AI gold rush. Is it the culmination of a visionary legacy or a symptom of market frenzy?

Clarevia Ventures' new partner isn't just another investor. She's a top analyst tasked with a critical mission: bridging the gap between science and patient impact.

Kardium’s landmark FDA win and a new wave of innovators signal a biotech boom, cementing British Columbia's status as a global hub for health innovation.

John Bratsakis, a 35-year veteran known for co-founding the innovative Plexcity cooperative, will take the helm of The League of Credit Unions & Affiliates.

With $4 billion raised, bootstrapped platform Donorbox proves smart tech can overcome philanthropy's challenges. Here's how they're doing it.

As tech IPOs stall, a new breed of private credit fund offers a lifeline to employees with 'paper wealth,' unlocking billions in value from top unicorns.

With a new $400M debt facility, Dyne Therapeutics is accelerating two promising drugs for DMD and DM1, showcasing the power of strategic, non-dilutive financing.

With veteran investor Travis Read as new President & COO, AmMax Bio signals a major push to accelerate its promising antibody-drug conjugate pipeline.

Oxford Financial Group's major Cincinnati expansion highlights a national trend: the strategic battle for top talent and regional dominance in wealth management.